Business context and reporting period
Entity mismatch: The request identifies Opus Genetics, Inc., but the supplied Form 10-K is for Ocuphire Pharma, Inc. This summary reflects the filing provided, not an Opus Genetics filing. It covers the fiscal year ended December 31, 2021; it is an annual report, not a standalone fourth-quarter report. The filing was signed March 24, 2022.
Ocuphire was a clinical-stage ophthalmic biopharmaceutical company with no approved products. Its lead candidate, Nyxol, was being developed for reversal of pharmacologically induced pupil dilation, presbyopia and night-vision disturbances. APX3330 was in development for diabetic retinopathy and diabetic macular edema. The company reported no product sales.
Financial performance and position
Amounts below are in U.S. dollars; figures are rounded to millions where appropriate.
| Metric | 2021 | 2020 |
|---|---|---|
| Collaboration revenue | $0.589 million | None |
| Research and development expense | $15.173 million | $6.648 million |
| General and administrative expense | $8.121 million | $2.818 million |
| Total operating expenses | $23.294 million | $19.968 million |
| Operating loss | $22.705 million | $19.968 million |
| Net loss | $56.693 million | $24.620 million |
| Net cash used in operating activities | $19.370 million | $6.797 million |
| Cash and cash equivalents at year-end | $24.534 million | $16.399 million |
- The $0.589 million of collaboration revenue came from licensing and technology-transfer arrangements for legacy Rexahn compound RX-3117, not from Ocuphire’s ophthalmic candidates.
- At December 31, 2021, current assets were $26.067 million and current liabilities were $3.855 million; total assets were $26.077 million. The balance sheet showed a $0.538 million short-term loan and no warrant liabilities. The filing states that the former convertible notes had converted to equity in 2020.
- There was no income-tax provision. Accumulated deficit was $89.368 million. The company reported no operating margin meaningful to a product business given immaterial collaboration revenue and ongoing development-stage losses.
Material changes versus 2020
- Net loss increased by $32.073 million, while operating loss increased by $2.737 million. R&D expense rose $8.525 million, mainly reflecting higher clinical-trial and manufacturing costs; G&A rose $5.303 million, including public-company costs and a $1.614 million noncash share settlement with investors.
- The largest contributor to the higher net loss was a $33.829 million noncash fair-value expense related to derivative and warrant liabilities. Series A warrants were reclassified from liabilities to equity after February 2021 waiver agreements; this accounting charge should be distinguished from cash operating burn.
- Operating cash use increased $12.573 million year over year. Financing provided $27.605 million in 2021, principally from a $15.0 million registered direct offering and $13.5 million of gross ATM proceeds, before issuance costs.
- Common shares outstanding increased from 10.883 million at year-end 2020 to 18.846 million at year-end 2021. The filing also reports substantial outstanding warrants and stock options, creating potential dilution.
Outlook, commentary, risks and unusual items
- Management said year-end cash was expected to fund operations into the second quarter of 2023, but the auditor’s report and management disclosures identify substantial doubt about the company’s ability to continue as a going concern. Ocuphire had no committed external funding and expected to need additional capital.
- Planned milestones, as stated in the filing, included reporting MIRA-3 Nyxol results around the end of Q1 2022; LYNX-1 and pediatric MIRA-4 results in Q2 2022; and ZETA-1 APX3330 results in the second half of 2022. Subject to successful and timely RM trial results, the company anticipated a Nyxol NDA filing in late 2022 under the 505(b)(2) pathway. These were forward-looking expectations, not reported outcomes.
- Key risks include clinical-trial failure or delay, evolving regulatory requirements for Nyxol’s drug-device combination presentation, reliance on contract manufacturers and CROs, and dependence on a single identified source for Nyxol drug substance and one supplier for APX3330 drug substance. COVID-19, supply-chain disruption, inflation and labor shortages could affect operations and financing.
- The Apexian sublicense carries up to $11 million in development and regulatory milestones, up to $20 million in sales milestones, and single-digit royalties on covered product sales. None were triggered or deemed probable at year-end. Payments under legacy Rexahn licensing arrangements are subject to a contingent value rights agreement; $91,000 had been paid under it in 2021.
- Ocuphire disclosed no legal proceeding expected to have a material adverse effect. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor was not engaged to opine on internal-control effectiveness.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Ocuphire Pharma, Inc. (ticker OCUP), not Opus Genetics, Inc.
- Check subsequent filings and announcements for actual Nyxol and APX3330 trial results, regulatory interactions and NDA progress against the timelines stated in this 10-K.
- Assess current cash, operating burn and financing access; the reported runway was a management estimate, and the auditor cited substantial doubt about going concern.
- Review dilution from equity raises, warrants, options and the equity-plan share reserve, and confirm any later exercises or issuances.
- Track manufacturing-source qualification and the potential Apexian milestone, royalty and license-continuity obligations.